Clinical Trial Update: Study of XL999 in Patients With Previously Treated Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of XL999 in previously treated ovarian cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• XL999

Snippet

Sponsor: Symphony Evolution, Inc. | Conditions: Ovarian Cancer | Phase 2 | Status: TERMINATED